Literature DB >> 21478804

Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up.

Hiroaki Bessho1, Shigeru Honda, Hisanori Imai, Akira Negi.   

Abstract

PURPOSE: To evaluate the natural course and possible funduscopic risk factors for polypoidal choroidal vasculopathy in a Japanese population.
METHODS: The records of 42 eyes from 41 patients (27 men and 14 women) diagnosed as having polypoidal choroidal vasculopathy located in the macula between November 1999 and October 2005 were retrospectively reviewed. The funduscopic findings at the first visit were evaluated. The changes in the best-corrected visual acuity (BCVA) from the baseline to 12 months were analyzed. The lesion types (clustered vs. nonclustered) found on indocyanine green angiography were compared for changes in the BCVA from the initial visit to 12 months.
RESULTS: The mean age of the subjects was 73.8 ± 8.0 years. The mean logarithm of the minimum angle of resolution (LogMAR) BCVA was 0.48 ± 4.0 at baseline and deteriorated to 0.75 ± 5.7 after 12 months, which was statistically significant (P = 0.00075). The mean LogMAR BCVA in the patients showing "nonclustered" polypoidal choroidal lesions on indocyanine green angiography was maintained for 12 months, while that of the "clustered" group decreased significantly during the same period (P = 0.0014).
CONCLUSION: Polypoidal choroidal vasculopathy did not show a favorable outcome in terms of the mean BCVA 12 months after the initial visit. The clustered polypoidal choroidal lesions on indocyanine green angiography may be related to poor prognosis of polypoidal choroidal vasculopathy over the natural course.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478804     DOI: 10.1097/IAE.0b013e31820d3f28

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.

Authors:  Meng Zhao; Hai-Ying Zhou; Jun Xu; Feng Zhang; Wen-Bin Wei; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

2.  Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.

Authors:  Akiko Miki; Shigeru Honda; Hiroshi Kojima; Masaya Nishizaki; Tomoko Nagai; Masashi Fujihara; Mamoru Uenishi; Mihori Kita; Yasuo Kurimoto; Akira Negi
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

3.  Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Naohiko Tanabe; Atsuki Kume; Hiroyuki Iijima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-17       Impact factor: 3.117

4.  Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Naohiko Tanabe; Seigo Yoneyama; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2016-09-23       Impact factor: 2.447

5.  Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.

Authors:  Jae Hyung Lee; Won Ki Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-03       Impact factor: 3.117

6.  The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients.

Authors:  Chui Ming Gemmy Cheung; Elizabeth Yang; Won Ki Lee; Gary K Y Lee; Ranjana Mathur; Jacob Cheng; Doric Wong; Tien Yin Wong; Timothy Y Y Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-27       Impact factor: 3.117

7.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

8.  Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Shigeru Honda; Hiroaki Bessho; Naoshi Kondo; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  Mol Vis       Date:  2012-11-22       Impact factor: 2.367

9.  Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.

Authors:  Wataru Matsumiya; Shigeru Honda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  BMC Ophthalmol       Date:  2013-04-04       Impact factor: 2.209

10.  Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.

Authors:  Maribel Fernández; María Gil; Francisco Gomez-Ulla; Pablo Charlón
Journal:  Case Rep Med       Date:  2012-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.